Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyramza +/- Paclitaxel in Elderly Gastric/GEJ Cancer
NCT03760822Phase 2Active, not recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Nov 2018
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Started Nov 2018; status: active, not recruiting.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03760822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760822.